Litigation Details for INTRA-CELLULAR THERAPIES, INC. v. SANDOZ INC. (D.N.J. 2024)

INTRA-CELLULAR THERAPIES, INC. v. SANDOZ INC. (D.N.J. 2024)

Docket		Date Filed	2024-03-28
Court	District Court, D. New Jersey	Date Terminated	2024-08-05
Cause	35:145 Patent Infringement	Assigned To	Jennifer Choe-Groves
Jury Demand	None	Referred To	Brendan Day
Patents	10,117,867; 10,464,938; 10,695,345; 10,960,009; 11,026,951; 11,052,084; 11,690,842; 11,753,419; 11,806,348; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; RE48,825; RE48,839
Link to Docket	External link to docket

Details for INTRA-CELLULAR THERAPIES, INC. v. SANDOZ INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-03-28				External link to document

Litigation summary and analysis for: INTRA-CELLULAR THERAPIES, INC. v. SANDOZ INC. (D.N.J. 2024)

Last updated: July 22, 2026

INTRA-CELLULAR THERAPIES v. Sandoz (3:24-cv-04327): Litigation Summary, Patent Claims, and Generic Risk Analysis

Intra-Cellular Therapies (ICT) is suing Sandoz in case 3:24-cv-04327 seeking to block Sandoz’s proposed generic launch tied to ICT’s key branded asset in this portfolio. The litigation posture at filing supports an exclusivity/patent-enforcement strategy rather than a purely manufacturing dispute, with the likely focal points being Orange Book-listed patents, ANDA Paragraph IV certifications, and motion practice around preliminary injunction timing.

What is the case caption, court, and filing timeline for ICT v. Sandoz 3:24-cv-04327?

Case: Intra-Cellular Therapies, Inc. v. Sandoz Inc.
Docket: 3:24-cv-04327
Parties:

• Plaintiff: Intra-Cellular Therapies, Inc. (ICT)
• Defendant: Sandoz Inc.

Core procedural expectation in Hatch-Waxman suits: Complaints typically follow an ANDA submission and a Paragraph IV act of infringement certification. The complaint framing typically includes counts under 35 U.S.C. § 271(e)(2) and requests for declaratory and injunctive relief tied to the Orange Book patent list.

What patents and claims are at issue in Intra-Cellular Therapies v. Sandoz 3:24-cv-04327?

Litigation in this case is analyzed under the standard Hatch-Waxman infringement structure:

Likely asserted patent categories

• Composition-of-matter patents covering the active pharmaceutical ingredient (API) or chemically defined forms.
• Method-of-use patents covering schizophrenia/bipolar indications, dosing regimens, or pharmacologic effects.
• Formulation patents covering extended-release or other delivery technologies (if the branded product uses such technology).
• Manufacturing/process patents (less common for primary injunction leverage, but sometimes asserted in parallel).

How the asserted claims usually map to ANDA Paragraph IV certifications

A Paragraph IV certification generally corresponds to one or more Orange Book patents, commonly followed by:

• Allegations that the proposed ANDA product infringes the asserted claims, either directly or under theories aligned with “will infringe upon approval.”
• Rebuttal positions that the proposed product does not infringe and/or that the asserted claims are invalid (anticipation, obviousness, indefiniteness, lack of enablement, or written description).

How does Paragraph IV ANDA certification drive the infringement theory in 3:24-cv-04327?

In Hatch-Waxman litigation, the operative infringement act is the ANDA “submission” with a Paragraph IV certification.

Typical structure

• ICT pleads that Sandoz’s ANDA filing, with Paragraph IV certifications for specified Orange Book patents, constitutes infringement under § 271(e)(2).
• Sandoz responds with:
  • Non-infringement positions (claim construction plus product-specific differences)
  • Invalidity arguments (the asserted claims do not meet statutory requirements)

Featured practical consequence

If ICT wins on infringement and validity of any asserted claim, Sandoz faces:

• Loss of ability to launch during the remaining patent term
• Additional time exposure depending on injunction scope and any appeal timelines

When does generic entry become possible after patent expiration or exclusivity in this dispute?

Generic entry timing depends on:

1. Whether any asserted patent remains in force at the relevant time; and
2. Whether an injunction is granted and survives appellate review.

How courts typically manage timing

• If ICT seeks a preliminary injunction, the court usually considers:
  • Likelihood of success on at least one asserted claim
  • Irreparable harm
  • Balance of hardships and public interest
• Hatch-Waxman cases often resolve quickly enough to affect launch calendars, but not always before the ANDA’s tentative approval window.

Key risk for Sandoz

Even if some asserted patents expire, infringement of a remaining asserted claim can still block launch unless the case resolves in Sandoz’s favor.

What is the Orange Book status of ICT patents implicated by 3:24-cv-04327?

Hatch-Waxman suits typically require that asserted patents are listed in the FDA Orange Book for the relevant NDA.

Orange Book checklist used in these cases

• Patent numbers and expiration dates asserted in the complaint
• Patent type codes (e.g., drug substance, drug product, method of use)
• Whether the patents are still listed and unexpired as of the complaint date
• Whether ICT asserted:
  • All listed patents, or
  • A subset tied directly to the Paragraph IV certification

How strong is ICT’s patent estate against Sandoz in this case?

Strength in Hatch-Waxman is assessed by claim-specific factors, not case caption posture.

Strength indicators typically relevant

• Independent claim breadth aligned to generic manufacturing reality
• Claim constructions that read on the proposed ANDA product
• Prior art gap: whether the asserted claims are meaningfully distinguishable over the closest references
• Correlation between asserted claims and Orange Book patentability record

Weakness indicators typically relevant

• Obviousness susceptibility based on crowded prior art
• Narrow claim terms that can be designed around
• Definiteness issues (especially for method-of-use language)
• Written description and enablement vulnerabilities for broad genus claims

What settlement or injunction outcomes are most likely in ICT v. Sandoz 3:24-cv-04327?

Settlement is common in Hatch-Waxman when:

• ICT has at least one claim with credible infringement reading on the ANDA product; and
• Sandoz sees launch economics aligned to:
  • a “carve-out” date for the infringing patent(s), or
  • a license with delayed entry

Common settlement outcomes

• Stipulated dismissal after agreed launch date
• Interim or final injunctions in exchange for broader licensing terms
• Non-monetary terms such as covenant-not-to-sue scoped to specific patents

Injunction scope

If granted, an injunction usually:

• Blocks launch of the ANDA product for the infringing claim(s)
• May not prevent future versions if design-around pathways exist

What generic entry risks exist for Sandoz if ICT wins on infringement or validity?

If ICT prevails on at least one asserted claim, Sandoz faces:

Operational impacts

• Launch delays, revised marketing plans, inventory write-down risk
• Need for design-around efforts (new formulation, different crystalline form, or changed dosing regimen)
• Potential for follow-on litigation if a design-around triggers a different asserted patent

Litigation leverage effects

• Courts’ claim construction decisions can lock in outcomes.
• A win on validity often reduces the chance of later challenges for the same claim set.

How does this litigation compare with other ICT patent enforcement against generics?

ICT’s typical enforcement style in the market generally centers on:

• A small set of Orange Book patents that align tightly with the most commercially critical product attributes.
• Early-stage pressure through motions for preliminary injunction or expediting.

In parallel, generic defendants often:

• Attack claim construction
• Raise obviousness/anticipation defenses using drug development and formulation prior art
• Argue non-infringement based on differences in formulation or dosing

(These patterns are common in Hatch-Waxman litigation and inform how outcomes are assessed in this docket.)

What is the regulatory pathway risk: ANDA approval vs. litigation stay?

Regulatory mechanics in play

• ANDA approval can occur during litigation, but launch is often blocked by patent remedies.
• FDA approval does not equal market entry if an injunction or settlement prevents launch.

Launch permissibility

The practical constraint is whether the court blocks launch for the specific product configuration covered by asserted claims.

Key Case-Decision Metrics to Track in 3:24-cv-04327

For business teams monitoring this docket, the most decision-relevant milestones in this class of cases include:

• Early claim construction orders (often the decisive fork)
• Summary judgment rulings on infringement/validity subsets
• Preliminary injunction orders and timelines for appeal
• Final judgment and infringement/invalidity determinations per asserted patent claim
• Settlement filings or consent judgments establishing a launch date

Key Takeaways

• The case 3:24-cv-04327 fits the standard Hatch-Waxman enforcement model: ICT asserts Orange Book-linked patents, and Sandoz defends against infringement and invalidity.
• The primary business risk for Sandoz is a court finding that at least one asserted claim is valid and infringed, which blocks launch and pressures settlement timing.
• Generic entry timing depends on the surviving asserted patents, not just the expiration dates of some individual patents.
• The most actionable intelligence signals are early claim construction, any preliminary injunction decision, and any settlement agreement specifying a launch carve-out.

FAQs

1) What happens to FDA ANDA approval if ICT wins the Hatch-Waxman case?
FDA approval can remain intact, but court relief typically prevents commercial launch until the injunction is lifted or a settlement carve-out date is reached.

2) Can Sandoz launch by changing formulation after an injunction?
Sometimes, but design-around must avoid infringement of any remaining asserted valid claims and may trigger new patent challenges.

3) What is the biggest driver of outcomes in ICT v. Sandoz-type cases?
Claim construction plus product-to-claim mapping for at least one asserted independent claim.

4) How do invalidity defenses typically succeed in these disputes?
By showing anticipation or obviousness over close prior art, or by undermining claim scope through indefiniteness, lack of written description, or enablement.

5) Does a settlement automatically mean non-infringement or invalidity?
No. Settlements often reflect risk allocation and business resolution rather than a merits finding.

---

References (APA)

1. Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).